Late-Breaking Science

When: Sunday, November 12, 2017, 3:45 p.m. - 5:00 p.m.
Where: Main Event I (Hall D, Main Building)

• TRiCS III – An International Multicenter Randomized Trial of Transfusion Triggers in Cardiac Surgery
   
• DACAB - Efficacy and Safety of Dual Acetylsalicylic Acid plus Ticagrelor or Ticagrelor Alone Antiplatelet Strategy after Coronary Artery Bypass Surgery at 12 months: Randomized Multicentre Trial
   
• PRESERVE - Sodium Bicarbonate and N-Acetylcysteine for the Prevention of Serious Adverse Outcomes Following Angiography
   
• BRUISE CONTROL-2 - A Randomized Controlled Trial of Continued versus Interrupted Novel Oral Anti-coagulant at the time of Device Surgery
   
• ABRIDGE J - Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial

When: Monday, November 13, 2017, 9:00 a.m. - 10:15 a.m.
Where: Ballroom CD, 3rd Level (Main Building)

• REAL-CAD - Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients with Stable Coronary Artery Disease
   
• REVEAL - Effects of Anacetrapib on the Incidence of New-onset Diabetes Mellitus and on Vascular Events in People with Diabetes
   
• FOURIER - Evolocumab and Outcomes in Patients with Peripheral Artery Disease
   
• FOURIER - Clinical Benefit of Evolocumab in Patients with a History of MI: An Analysis from FOURIER
   
• CANTOS - Residual Inflammatory Risk and Residual Cholesterol Risk: Critical Analysis from the CANTOS Trial
   

When: Monday, November 13, 2017, 10:45 a.m. - 12:00 noon
Where: Main Event I (Hall D, Main Building)

• Chinese BP Trial - Time at Blood Pressure Target and the Risk of Cardiovascular Diseases and Mortality
   
• SPRINT - Blood Pressure Measurement in the Systolic Blood Pressure Intervention Trial (SPRINT)
   
• GATEWAY - Effects of Bariatric Surgery in Obese Patients with Hypertension
   

When: Monday, November 13, 2017, 3:45 p.m. - 5:00 p.m.
Where: Ballroom CD, 3rd Level (Main Building)

• CANVAS - Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results from the CANVAS Program
   
• EXSCEL - Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: Insights from the EXSCEL Trial
   
• EMPA-REG OUTCOME - Empagliflozin Reduces Mortality and Hospitalization for Heart Failure in Patients with Type 2 Diabetes and Peripheral Artery Disease: A Sub-Analysis of the EMPA-REG OUTCOME Trial
   
• BiomarCaRE - Serum Metabolomic Profiles Predict Coronary Heart Disease in the General Population - The Biomarcare Consortium
   

When: Tuesday, November 14, 2017, 10:45 a.m. - 12:00 noon
Where: Main Event I (Hall D, Main Building)

• COMPASS - Costs Impact Rivaroxaban Plus Aspirin Versus Aspirin in the COMPASS Trial
   
• RE-DUAL PCI - Subgroup Analysis from the RE-DUAL PCI Trial: Dual Antithrombotic Therapy with Dabigatran in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
   
• POISE-2 PCI Substudy - Aspirin in Patients with Previous Percutaneous Coronary Intervention (PCI) Undergoing Noncardiac Surgery
   
• GEMINI-ACS-1 - P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes
   
• PRAGUE-18 - One-year Outcomes of Patients with Acute Myocardial Infarction Treated with Primary Angioplasty and Randomized to Prasugrel versus Ticagrelor - The Prague-18 Trial
   

When: Tuesday, November 14, 2017, 3:45 p.m. - 5:00 p.m.
Where: Ballroom CD, 3rd Level (Main Building)

• SWEDEHEART registry results 1995-2014 - Improved Outcomes in Patients with Non-ST-Elevation Myocardial Infarction During 20 years are Related to Implementation of Evidence-Based Treatments
   
• STIC2IT - Results of the Study of a Tele-pharmacy Intervention for Chronic Diseases to Improve Treatment Adherence (STIC2IT)
   
• ACS QUIK - Effect of a Quality Improvement Toolkit on Acute Myocardial Infarction in India: The ACS QUIK Cluster Randomized, Stepped Wedge Trial
   
• NZ STEP WEDGE - National Implementation Of A Clinical Guidance Framework for the Emergency Department Assessment of Patients with Possible Acute Coronary Syndromes
   
• DECIDE-LVAD - Effectiveness of a Shared Decision Making Intervention for Patients Offered a Destination Therapy Left Ventricular Assist Device for End-Stage Heart Failure: the DECIDE-LVAD Trial
   
• STEMI ACCELERATOR-2 - Regional STEMI Systems of Care: Results of the Mission: Lifeline STEMI ACCELERATOR-2 Study
   

When: Wednesday, November 15, 2017, 9:00 a.m. - 10:15 a.m.
Where: Ballroom CD, 3rd Level (Main Building)

• REDUCE LAP-HF - Transcatheter InterAtrial Shunt Device for the Treatment of Heart Failure: Results from the REDUCE LAP-HF I Randomized Controlled Trial
   
• TNT-POAF - Temporary Neurotoxin Treatment to Prevent Postoperative Atrial Fibrillation
   
• PROPEL - Granulocyte Macrophage Colony-Stimulating Factor with and without Supervised Exercise to Improve Walking Performance in Peripheral Artery Disease
   
• ALLSTAR - 6-Month Results of ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: A Randomized, placebo-controlled, double-blind study
   
• HOPE-Duchenne - Cardiosphere-derived cells for the Treatment of Duchenne Cardiomyopathy: Results of the Halt cardiOmyopathy ProgrEssion [HOPE]-Duchenne Trial